Evidence map›Paper›PMID 35606324›Full record

SynthesisJournal of pediatric urology2022

Clinicopathologic predictors of outcomes in children with stage I testicular germ cell tumors: A pooled post hoc analysis of trials from the Children's Oncology Group.

Nirmish Singla, Justin Wong, Shyamli Singla, Mark Krailo, Li Huang, Furqan Shaikh, Deborah Billmire, Frederick Rescorla, Jonathon Ross, Bryan Dicken and 3 more

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of pediatric urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 2 countries.

Nirmish SinglaDepartments of Urology and Oncology, the James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Justin WongUniversity of Texas Southwestern Medical School, Dallas, TX, USA.
Shyamli SinglaPediatric Specialists of Virginia, Fairfax, VA, USA.
Mark KrailoUniversity of Southern California, Los Angeles, CA, USA; Childrens Oncology Group, USA.
Li HuangChildrens Oncology Group, USA.
Furqan ShaikhThe Hospital for Sick Children, Toronto, Canada.
Deborah BillmireIndiana University, Bloomington, IN, USA.
Frederick RescorlaIndiana University, Bloomington, IN, USA.
Jonathon RossRainbow Babies and Childrens Hospital, Cleveland, OH, USA.
Bryan DickenUniversity of Alberta, Canada.
James F AmatrudaUniversity of Southern California, Los Angeles, CA, USA; Department of Pediatrics, Childrens Hospital Los Angeles, Los Angeles, CA, USA.
A Lindsay FrazierDana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Aditya BagrodiaDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, University of California San Diego, La Jolla, San Diego, CA, USA. Electronic address: bagrodia@health.ucsd.edu.
Indiana University Bloomington · USUniversity of Southern California · USChildren's Oncology Group · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · USHospital for Sick Children · CAJohns Hopkins University · USRainbow Babies & Children's Hospital · USThe University of Texas Southwestern Medical Center · USUniversity of Alberta · CAUniversity of California San Diego · USVirginia Cancer Specialists · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

backgroundPatients with clinical stage I (CS I: cN0M0) testicular germ cell tumors (TGCT) exhibit favorable oncologic outcomes. While prognostic features can help inform treatment in adults with CS I TGCT, we lack reliable means to predict relapse among pediatric and adolescent patients.

objectiveWe sought to identify predictors of relapse in children with CS I TGCT. STUDY

designWe performed a pooled post hoc analysis on pediatric and adolescent AJCC CS I TGCT patients enrolled in 3 prospective trials: INT-0097 (phase II), INT-0106 (phase III), and AGCT0132 (phase III). Pathology was centrally reviewed. Patient demographics, pT stage, serum tumor markers, margin status, histology, relapse, and survival were compiled. Cox regression analyses were used to identify predictors of events, defined as relapse, secondary malignant neoplasm, or death.

results106 patients were identified with outcomes data available. Most patients were pT1-2 stage. Among patients with evaluable histopathology, yolk sac tumor elements were present in all patients and lymphovascular invasion in 51% of patients. Over a median follow-up of 56 months, no patients died, and 25 patients (24%) experienced an event (median event-free survival not reached). Independent predictors of events on multivariable analysis included age ≥12 years at diagnosis (HR 8.87, p < 0.001) and higher pT stage (pT2 HR 7.31, p = 0.0017; pT3 HR 13.5, p = 0.0043). DISCUSSION: Although our study population reflects the largest pooled prospective cohort of CS I pediatric and adolescent TGCT to our knowledge, the relatively low event rate limits our multivariable analysis, and longer follow-up duration would help further characterize the natural history of these patients. Centralized pathologic review was also unable to be performed for several patients.

conclusionPediatric and adolescent CS I TGCT patients exhibit remarkable 5-year survival. Using combined data from multiple prospective trials, our study identifies clinicopathologic features that predict relapse and inform personalized treatment for these patients by potentially guiding surveillance versus adjuvant treatment strategies.

Indexed as

Neoplasms, Germ Cell and EmbryonalTesticular NeoplasmsAdolescentChildClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicHumansMaleNeoplasm StagingProspective StudiesRecurrenceChildrenClinical stage IGerm cell tumorPredictorsRelapseTestis cancer

Identifiers

PMID35606324
PMCPMC9667350
OpenAlexW4229044027

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.